HomeNewsBusinessMarketsInvestors should rebalance their portfolio; largecaps a better play: Mahesh Patil

Investors should rebalance their portfolio; largecaps a better play: Mahesh Patil

Small-ticket consumer discretionary sector which have corrected can bounce back. Private banks have seen a sharp correction, and insurance companies should continue to see secular growth.

April 01, 2020 / 12:51 IST
Story continues below Advertisement

Investors should rebalance their asset allocation. Wherever the equity component goes down due to the fall in the market, investors should increase their equity exposure while maintaining a balanced allocation, and there can be a slight tilt to large-caps at this time, Mahesh Patil, CIO – Equity, Aditya Birla Sun Life AMC, said in an interview with Moneycontrol’s Kshitij Anand.

Edited excerpt:

Story continues below Advertisement

Q) It looks like we have formed a base near the swing low of 7,511. What is your take on the market action?
A) Indian equity markets have fallen 30-35 percent from the recent peak in mid-Feb. This is not just on the account of fundamental reasons but also due to high-intensity selling by foreign investors (FIIs) who have sold more than USD 8 billion in the past few weeks.

The sharp sell-off by FIIs is primarily from Quant funds, Hedge funds, Risk parity funds which had grown massively, some on leverage, when global liquidity was easy.

They had to forcefully unwind their positions amidst the high volatility as the VIX index touched record highs.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show